Therapeutics targeting the innate immune system

Nature Reviews Immunology

Volumn 4, Issue 7, 2004, Pages 512-520

  Ulevitch, Richard J ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MYELOID DIFFERENTIATION FACTOR 88; NOD PROTEIN; NUCLEOTIDE BINDING PROTEIN; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DRUG TARGETING; HOST; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOCHEMISTRY; IMMUNOMODULATION; INNATE IMMUNITY; MICROBIAL IMMUNITY; NONHUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW;

EID: 3142779901     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri1396     Document Type: Review

References (98)

1. Yamamoto, M., Takeda, K. & Akira, S. TIR domain-containing adaptors define the specificity of TLR signaling. Mol. Immunol. 40, 861-868 (2004).
2. Beutler, B., Hoebe, K., Du, X. & Ulevitch, R. J. How we detect microbes and respond to them: the Toll-like receptors and their transducers. J. Leukoc. Biol. 74, 479-485 (2003).
3. Underhill, D. M. Toll-like receptors: networking for success. Eur. J. Immunol. 88, 1767-1775 (2003).
4. O'Neill, L. A. The role of MyD88-like adapters in Toll-like receptor signal transduction. Biochem. Soc. Trans. 31, 643-647 (2003).
5. Dunne, A. & O'Neill, L. A. The interleukin-1 receptor/Toll-like receptor superfamily: signal transduction during inflammation and host defense. Sci. STKE [online] 2003, re3 (2003).
6. Takeda, K., Kaisho, T. & Akira, S. Toll-like receptors. Annu. Rev. Immunol. 21, 335-376 (2003).
7. Chamaillard, M., Girardin, S. E., Viala, J. & Philpott, D. J. Nods, Nalps and Nalp: intracellular regulators of bacterial-induced inflammation. Cell. Microbiol. 5, 581-592 (2003).
8. Inohara, N. & Nunez, G. NODs: intracellular proteins involved in inflammation and apoptosis. Nature Rev. Immunol. 5, 371-382 (2003).
9. Akira, S. & Takeda, K. Toll-like receptor signalling. Nature Rev. Immunol. 4, 499-511 (2004).
10. Girardin, S. E. et al. Peptidoglycan molecular requirements allowing detection by Nod1 and Nod2. J. Biol. Chem. 278, 41702-41708 (2003).
11. Chamaillard, M. et al. An essential role for NOD1 in host recognition of bacterial peptidoglycan containing diaminopimelic acid. Nature Immunol. 4, 702-707 (2003).
12. Girardin, S. E. et al. Nod1 detects a unique muropeptide from Gram-negative bacterial peptidoglycan. Science 300, 1584-1587 (2003). Provides the first definition of the structural requirements of the NOD1 ligand.
13. O'Neill, L. A. et al. Mal and MyD88: adapter proteins involved in signal transduction by Toll-like receptors. J. Endotoxin Res. 9, 55-59 (2003).
14. Martin, M. U. & Wesche, H. Summary and comparison of the signaling mechanisms of the Toll/Interleukin-1 receptor family. Biochim. Biophys. Acta 1592, 265-268 (2002).
15. O'Neill, L. A., Fitzgerard, K. A. & Bowie, A. G. The Toll-IL-1 receptor adaptor family grows to five members. Trends Immunol. 24, 286-290 (2003).
16. Ogura, Y. et al. Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-κB. J. Biol. Chem. 276, 4812-4818 (2001).
17. Kobayashi, K. et al. RICK/Rip2/CARDIAK mediates signalling for receptors of the innate and adaptive immune systems. Nature 416, 194-199 (2002). Provides important evidence implicating RICK in both TLR- and NOD-protein signalling pathways.
18. Hoffmann, J. A. The immune response of Drosophila. Nature 426, 33-38 (2003).
19. Gobert, V. et al. Dual activation of the Drosophila Toll pathway by two pattern recognition receptors. Science 302, 2126-2130 (2003).
20. Imler, J. L. & Hoffmann, J. A. Toll signaling: the TIReless quest for specificity. Nature Immunol. 4, 105-106 (2003).
21. Gottar, M. et al. The Drosophila immune response against Gram-negative bacteria is mediated by a peptidoglycan recognition protein. Nature 416, 640-644 (2002). Provides a new paradigm that describes different arms of the innate immune response in insects.
22. Zhang, D. et al. A Toll-like receptor that prevents infection by uropathogenic bacteria. Science 303, 1522-1526 (2004).
23. Nishiya, T. & DeFranco, A. L. Ligand-regulated chimeric receptor approach reveals distinctive subcellular localization and signaling properties of the Toll-like receptors. J. Biol. Chem. 279, 19008-19017 (2004).
24. Miyake, K. Endotoxin recognition molecules, Toll-like receptor 4-MD-2. Semin. Immunol. 16, 11-16 (2004).
25. Akashi, S. et al. Lipopolysaccharide interaction with cell surface Toll-like receptor 4-MD-2: higher affinity than that with MD-2 or CD14. J. Exp. Med. 198, 1035-1042 (2003).
26. Wetzler, L. M. The role of Toll-like receptor 2 in microbial disease and immunity. Vaccine 21, S55-S60 (2003).
27. Kirschning, C. J. & Schumann, R. R. TLR2: cellular sensor for microbial and endogenous molecular patterns. Curr. Top. Microbiol. Immunol. 270, 121-144 (2002).
28. Hajjar, A. M. et al. Cutting edge: Functional interactions between Toll-like receptor (TLR) 2 and TLR1 or TLR6 in response to phenol-soluble modulin. J. Immunol. 166, 15-19 (2001).
29. Ozinsky, A. et al. The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between Toll-like receptors. Proc. Natl Acad. Sci. USA 97, 13766-13771 (2000). Provides key data showing how TLRs comprise heteromeric subunits that determine ligand specificity.
30. Mizel, S. B., Honko, A. N., Moors, M. A., Smith, P. S. & West, A. P. Induction of macrophage nitric oxide production by Gram-negative flagellin involves signaling via heteromeric Toll-like receptor 5/Toll-like receptor 4 complexes. J. Immunol. 170, 6217-6223 (2003).
31. Schulze-Lefert, P. Plant immunity: the origami of receptor activation. Curr. Biol. 14, R22-R24 (2004).
32. Nimchuk, Z., Eulgem, T., Holt, B. F. & Dangl, J. L. Recognition and response in the plant immune system. Annu. Rev. Genet. 37, 579-609 (2003).
33. Martin, G. B., Bogdanove, A. J. & Sessa, G. Understanding the functions of plant disease resistance proteins. Annu. Rev. Plant Biol. 54, 23-61 (2003).
34. Martinon, F. & Tschopp, J. Inflammatory caspases; linking an intracellular innate immune system to autoinflammatory diseases. Cell 117, 561-574 (2004).
35. Tanabe, T. et al. Regulatory regions and critical residues of NOD2 involved in muramyl dipeptide recognition. EMBO J. 23, 1587-1597 (2004).
36. Lund, J., Sato, A., Akira, S., Medzhitov, R. & Iwasaki, A. Toll-like receptor 9-mediated recognition of Herpes simplex virus-2 by plasmacytoid dendritic cells. J. Exp. Med. 198, 513-520 (2003).
37. Krug, A. et al. Herpes simplex virus type 1 activates murine natural interferon producing cells through Toll-like receptor 9. Blood 103, 1433-1437 (2004).
38. Kaisho, T. & Akira, S. Regulation of dendritic cell function through Toll-like receptors. Curr. Mol. Med. 3, 373-385 (2003).
39. El Biaze, M. et al. T cell activation, from atopy to asthma: more a paradox than a paradigm. Allergy 58, 844-853 (2003).
40. Hussain, I. & Kline, J. N. CpG oligodeoxynucleotides: a novel therapeutic approach for atopic disorders. Curr. Drug Targets Inflamm. Allergy 2, 199-205 (2003).
41. Kuchroo, V. K., Umetsu, D. T., DeKruyff, R. H. & Freeman, G. J. The TIM gene family: emerging roles in immunity and disease. Nature Rev. Immunol. 3, 454-462 (2003).
42. Melief, C. J. Strategies for immunotherapy of cancer. Adv. Immunol. 75, 235-282 (2000).
43. Hess, J., Schaible, U., Raupach, B. & Kaufmann, S. H. Exploiting the immune system: toward new vaccines against intracellular bacteria. Adv. Immunol. 75, 1-88 (2000).
44. Kaisho, T. & Akira, S. Toll-like receptors as adjuvant receptors. Biochim. Biophys. Acta 1589, 1-13 (2002).
45. Jiang, Z. H. & Koganty, R. R. Synthetic vaccines: the role of adjuvants in immune targeting. Curr. Med. Chem. 10, 1423-1439 (2003).
46. Evans, J. T. et al. Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi. 529. Expert Rev. Vaccines 2, 219-229 (2003).
47. Persing, D. H. Taking Toll: lipid A mimetics as adjuvants and immunomodulators. Trends Microbiol. 10, S32-S37 (2002).
48. Stover, A. G. et al. Structure-activity relationship of synthetic Toll-like receptor 4 agonists. J. Biol. Chem. 279, 4440-4449 (2004).
49. Heil, F. et al. Species-specific recognition of single-stranded RNA via Toll-like receptor 7 and 8. Science 303, 1526-1529 (2004). Identifies a naturally occurring ligand for TLR 7 and TLR 8.
50. Diebold, S. S., Kaisho, T., Hemmi, H., Akira, S. & Reis e Sousa, C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303, 1529-1531 (2004). Identifies a naturally occurring ligand for TLR7.
51. Skinner R. B. Jr. Imiquimod. Dermatol. Clin. 21,291-300 (2003).
52. Hengge, U. R. & Cusini, M. Topical immunomodulators for the treatment of external genital warts, cutaneous warts and molluscum contagiosum. Br. J. Dermatol. 149 (Suppl. 66), 15-19 (2003).
53. Bernard, H. U. Established and potential strategies against papillomavirus infections. J. Antimicrob. Chemother. 53, 137-139 (2004).
54. Akira, S. & Hemmi, H. Recognition of pathogen-associated molecular patterns by TLR family. Immunol. Lett. 85, 85-95 (2003).
55. Heil, F. et al. The Toll-like receptor 7 (TLRT)-specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily. Eur. J. Immunol. 33, 2987-2997 (2003).
56. Hemmi, H. et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nature Immunol. 3, 196-200 (2002).
57. Baldridge, J. R. et al. Immunostimulatory activity of aminoalkyl glucosaminice 4-phosphates (AGPs): induction of protective innate immune responses by RC-524 and RC-529. J. Endotoxin Res. 8, 453-458 (2002).
58. Kurt-Jones, E. A. et al. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nature Immunol. 1, 398-401 (2000). Among the first reports to indicate a role for the innate immune system in antiviral responses.
59. Doyle, S. et al. IRF3 mediates a TLR3/TLR4-specific antiviral gene program. Immunity 17, 251-263 (2002).
60. Hoebe, K. & Beutler, B. LPS, dsRNA and the interferon bridge to adaptive immune responses: Trif, Tram, and other TIR adaptor proteins. J. Endotoxin Res. 10, 130-136 (2004).
61. Tabeta, K. et al. Toll-like receptors 9 and 3 as essential components of innate immune defense against mouse cytomegalovirus infection. Proc. Natl. Acad. Sci. USA 101, 3516-3521 (2004).
62. Hoebe, K. et al. Upregulation of costimulatory molecules induced by lipopolysaccharide and double-stranded RNA occurs by Trif-dependent and Trif-independent pathways. Nature Immunol. 4, 1223-1229 (2003).
63. Beutler, B. et al. Lps2 and signal transduction in sepsis: at the intersection of host responses to bacteria and viruses. Scand. J. Infect. Dis. 35, 563-567 (2003).
64. Honda, K. et al. Selective contribution of IFN-α/β signaling to the maturation of dendritic cells induced by double-stranded RNA or viral infection. Proc. Natl Acad. Sci. USA 100, 10872-10877 (2003).
65. Matsumoto, M., Funami, K., Oshiumi, H. & Seya, T. Toll-like receptor 3: a link between Toll-like receptor, interferon and viruses. Microbiol. Immunol. 48, 147-154 (2004).
66. Heit, A. et al. Cutting edge: Toll-like receptor 9 expression is not required for CpG DNA-aided cross-presentation of DNA-conjugated antigens but essential for cross-priming of CD8 T cells. J. Immunol. 170, 2802-2805 (2003).
67. Heit, A. et al. CpG-DNA aided cross-priming by cross-presenting B cells. J. Immunol. 172, 1501-1507 (2004).
68. Speigelberg, H. L., Homer, A. A., Takabayashi, K. & Raz, E. Allergen-immunostimulatory oligodeoxynucleotide conjugate: a novel allergoid for immunotherapy. Curr. Opin. Allergy Clin. Immunol. 2, 547-551 (2002).
69. Karin, M., Yamamoto, Y. & Wang, Q. M. The IKK NF-κB system: a treasure trove for drug development. Nature Rev. Drug Discov. 3, 17-26 (2004).
70. Arkin, M. R. & Wells, J. A. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nature Rev. Drug Discov. 3, 301-317 (2004).
71. Vassilev, L. T. et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844-848 (2004).
72. Bartfai, T. et al. A low molecular weight mimic of the Toll/IL-1 receptor/resistance domain inhibits IL-1 receptor-mediated responses. Proc. Natl Acad. Sci. USA 100, 7971-7976 (2003). Provides the first evidence indicating that it is possible to target TIR-TIR domain interactions with a small molecule.
73. Heikenwalder, M. et al. Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nature Med. 10, 187-192 (2004).
74. Hoebe, K. et al. Identification of Lps2 as a key transducer of MyD88-independent TIR signalling. Nature 424, 743-748 (2003). This seminal paper describes the use of forward genetics to decipher TLR-signalling pathways and identifies Lps2 as a gene encoding TRIF.
75. Kawai, T., Adachi, O., Ogawa, T., Takeda, K. & Akira, S. Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity 11, 115-122 (1999).
76. Yamamoto, M. et al. TRAM is specifically involved in the Toll-like receptor 4-mediated MyD88-independent signaling pathway. Nature Immunol. 4, 1144-1150 (2003).
77. Fitzgerald, K. A. et al. LPS-TLR4 signaling to IRF-3/7 and NF-κB involves the Toll adapters TRAM and TRIF. J. Exp. Med. 198, 1043-1055 (2003).
78. Drachenberg, K. J., Heinzkill, M., Urban, E. & Woroniecke, S. R. Efficacy and tolerability of short-term specific immunotherapy with pollen allergoids adjuvanted by monophosphoryl lipid A (MPL) for children and adolescents. Allergol. Immunopathol. (Madr.) 31, 270-277 (2003).
79. Mothes, N. et al. Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. Clin. Exp. Allergy 33, 1198-1208 (2003).
80. Bienzle, U. et al. Immunization with an adjuvant hepatitis B vaccine after liver transplantation for hepatitis B-related disease. Hepatology 38, 811-819 (2003).
81. Vernacchio, L. et al. Effect of monophosphoryl lipid A (MPL) on T-helper cells when administered as an adjuvant with pneumocococcal-CRM197 conjugate vaccine in healthy toddlers. Vaccine 20, 3658-3667 (2002).
82. Lynn, M. et al. Extended in vivo pharmacodynamic activity of E5564 in normal volunteers with experimental endotoxemia. J. Pharmacol. Exp. Ther. 308, 175-181 (2004).
83. Wong, Y. N. et al. Safety, pharmacokinetics, and pharmacodynamics of E5564, a lipid A antagonist, during an ascending single-dose clinical study. J. Clin. Pharmacol. 43, 735-742 (2003).
84. Liang, E. et al. Pharmacokinetics of E5564, a lipopolysaccharide antagonist, in patients with impaired hepatic function. J. Clin. Pharmacol. 43, 1361-1369 (2003).
85. Agarwala, S. S., Kirkwood, J. M. & Bryant, J. Phase 1, randomized, double-blind trial of 7-allyl-8-oxoguanosine (loxoribine) in advanced cancer. Cytokines Cell. Mol. Ther. 6, 171-176 (2000).
86. Sauder, D. N., Smith, M. H., Senta-McMillian, T., Soria, I. & Meng T. C. Randomized, single-blind, placebo-controlled study of topical application of the immune response modulator resiquimod in healthy adults. Antimicrob. Agents Chemother. 47, 3846-3852 (2003).
87. Jones, T. Resiquimod 3M. Curr. Opin. Investig. Drugs 4, 214-218 (2003).
88. Imiquimod (Aldara) for actinic keratoses. Med. Lett. Drugs Ther. 46, 42-44 (2004).
89. Prinz, B. M. et al. Treatment of Bowen's disease with imiquimod 5% cream in transplant recipients, Transplantation 77, 790-791 (2004).
90. Kreuter, A. et al. Treatment of anal intraepithelial neoplasia in patients with acquired HIV with imiquimod 5% cream. J. Am. Acad. Dermatol. 50, 980-981 (2004).
91. Huber, A. et al. Topical imiquimod treatment for nodular basal cell carcinomas: an open-label series. Dermatol. Surg. 30, 429-430 (2004).
92. Herbert, W. C. Imiquimod and the treatment of cutaneous T-cell proliferative diseases: at the threshold. Skinmed. 2, 273-274 (2003).
93. Leifer, C. A., Verthelyi, D. & Klinman, D. M. Heterogeneity in the human response to immunostimulatory CpG oligodeoxynucleotides. J. Immunother. 26, 313-319 (2003).
94. Tulic, M. K. Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response. J. Allergy Clin. Immunol. 113, 234-241 (2004).
95. Bohle, B. AIC. Dynavax. Curr. Opin. Investig. Drugs 4, 603-607 (2003).
96. Immunostimulatory DNA-Dynavax. AIC, Amb a 1 immunostimulatory conjugate, HBV-ISS, ISS 1018, ISS DNA, ISS DNA-dynavax, ISS1, ISS2. Drugs R D 3, 193-196 (2002).
97. Paul, S. Technology evaluation: CpG-7909, Coley. Curr. Opin. Mol. Ther. 5, 553-559 (2003).
98. Medzhitov, R., Preston-Hurlburt, P. & Janeway, C. A. Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388, 394-397 (1997).